134 related articles for article (PubMed ID: 30539876)
21. Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Wang HK; Xu WH; Ma CG; Zhou LP; Shi GH; Zhang HL; Ye DW
Int J Urol; 2019 Jan; 26(1):75-82. PubMed ID: 30325072
[TBL] [Abstract][Full Text] [Related]
22. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Beck J; Bellmunt J; Escudier B
Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
24. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Dudek AZ; Raza A; Chi M; Singhal M; Oberoi R; Mittapalli RK; Agarwal S; Elmquist WF
Clin Genitourin Cancer; 2013 Jun; 11(2):155-60. PubMed ID: 23265925
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
26. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
27. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
29. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous regression of brain metastasis secondary to renal cell carcinoma.
Guthbjartsson T; Gíslason T
Scand J Urol Nephrol; 1995 Jun; 29(2):215-7. PubMed ID: 7569801
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
[TBL] [Abstract][Full Text] [Related]
33. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
34. Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Hasegawa Y; Mita K; Matsubara A; Ohdan H
Int J Clin Oncol; 2009 Oct; 14(5):465-7. PubMed ID: 19856059
[TBL] [Abstract][Full Text] [Related]
35. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
Qin S; Zhang S
Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
[No Abstract] [Full Text] [Related]
36. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
37. Solitary brain metastasis from renal cell carcinoma 14 years after nephrectomy: a case report.
Ishikawa J; Umezu K; Yamashita H; Maeda S
Hinyokika Kiyo; 1990 Dec; 36(12):1439-41. PubMed ID: 2075881
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Maroto JP; del Muro XG; Mellado B; Perez-Gracia JL; Andrés R; Cruz J; Gallardo E; Domenech M; Arranz JA; Meana JA
Clin Transl Oncol; 2013 Sep; 15(9):698-704. PubMed ID: 23359179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]